

**Abstract number:** Euro18A-POS415

**Abstract type:** Poster

**Reference:** This abstract is a part of the EuroPCR 2018 programme, 22-25 May 2018, Paris

**Link:** <https://abstractbook.pconline.com/export/pdf/id/100587>

**Published on:** 15 May 2018

## **Clinical outcomes of ultrathin strut biodegradable polymer-coated everolimus-eluting coronary stent system in treatment of patient with de novo coronary artery lesions**

PATTED S. V. (1), CHINCHOLI A. S. (1), THAKKAR A. (2)

(1) KLE Academy of Higher Education & Research Centre, Belgaum INDIA(2) Meril Life Sciences, Pvt. Ltd., Vapi INDIA

**THEME:** Coronary Interventions

**TOPIC(S):** Stents and scaffolds

### **AIMS**

Evermine 50? everolimus-eluting coronary stent (EES) is a novel ultrathin strut (50 µm) cobalt-chromium coronary drug-eluting stent platform coated with biodegradable polymer. The purpose of Evermine 50 EES-KLES study was to evaluate clinical safety and performance of Evermine 50 EES in patients with de novo coronary artery lesions.

### **METHODS AND RESULTS**

This was single-arm, single-centre, non-randomized study, and carried-out in 171 patients in which 246 lesions were treated with Evermine 50 EES. The major endpoint was major adverse cardiac events (MACE) which is a composite of cardiac death, any myocardial infarction (MI) and ischemia-driven target lesion revascularization (ID-TLR) at 6 and 12-month follow-up. The study population included higher number of male 139 (81.29%) and average mean age was 57.85 ± 10.05 years. Diabetes was present in 70 (40.94%) patients and 69 (40.35%) had hypertension. The rate of MACE was 1 (0.66%) and 3 (2.04%) which represented similar percentage of cardiac death at 6 and 12-month follow-up, respectively. There were no ID-TLR and MI reported, and no any stent thrombosis during the follow-up period. CTRI Number: CTRI/2017/09/009939.

### **CONCLUSIONS**

This study revealed favourable clinical safety and performance of Evermine 50 everolimus-eluting coronary stent in de novo coronary artery lesions patients.